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The effect of metabolic syndrome components
on exercise performance in patients with
intermittent claudication
Andrew W. Gardner, PhD,a and Polly S. Montgomery, MS,b Oklahoma City, Okla; and Baltimore, Md
Purpose: To determine the effect of metabolic syndrome components on intermittent claudication, physical function,
health-related quality of life, and peripheral circulation in patients with peripheral arterial disease (PAD), and to identify
the metabolic syndrome components most predictive of each outcome measure.
Methods: Patients limited by intermittent claudication with three (n 48), four (n 45), or five (n 40) components
of metabolic syndrome were studied. Patients were assessed on PAD-specific measures consisting of ankle-brachial
index (ABI), initial claudication distance, absolute claudication distance, physical function measures, health-related
quality of life, and calf blood flow and transcutaneous oxygen tension responses after 3 minutes of vascular
occlusion.
Results: Initial claudication distance (mean  SD) progressively declined (P  .019) in those with three (203  167 m),
four (124  77 m), and five (78  57 m) metabolic syndrome components, and absolute claudication distance
progressively declined (P  .036) in these groups as well (414  224 m vs 323  153 m vs 249  152 m, respectively).
Furthermore, compared with patients with only three components of metabolic syndrome, those with all five components
had impaired values (P < .05) for peak oxygen uptake, ischemic window, 6-minute walk distance, self-perceived walking
ability and health, daily physical activity, health-related quality of life on six of eight domains, calf hyperemia, and calf
ischemia after vascular occlusion. Abdominal obesity was the predictor (P < .05) of exercise performance during the
treadmill and 6-minute walk tests, as well as physical activity. Elevated fasting glucose was the predictor (P < .05) of
peripheral vascular measures, self-perceived walking ability and health, and health-related quality of life.
Conclusion: PAD patients with more metabolic syndrome components have worsened intermittent claudication, physical
function, health-related quality of life, and peripheral circulation. Abdominal obesity and elevated fasting glucose are the
metabolic syndrome components that are most predictive of these outcome measures. Aggressively treating these
metabolic syndrome components may be particularly important in managing symptoms and long-term prognosis of PAD
patients. ( J Vasc Surg 2008;47:1251-8.)Intermittent claudication is a symptom of peripheral
arterial disease (PAD) and is associated with elevated
rates of mortality1-4 and morbidity.5 Intermittent clau-
dication afflicts 5% of the United States population aged
older than 55 years6 and occurs during ambulation when
the peripheral circulation is inadequate to meet the
metabolic requirement of the active leg musculature. As
a consequence, patients with intermittent claudication
have ambulatory dysfunction7,8 that limits daily physical
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life.10
Patients limited by intermittent claudication also
have numerous comorbid conditions.11 Many of these
cardiovascular risk factors are associated with insulin
resistance12 and are clustered in a pattern characteristic
of metabolic syndrome.13 Metabolic syndrome increases
the risk of cardiovascular mortality14 and worsening
PAD.15 As a consequence, patients with intermittent
claudication and metabolic syndrome have further limi-
tations in exercise performance,16,17 health-related qual-
ity of life,16 and peripheral circulation16 than patients
without metabolic syndrome, as well as a greater rate of
mortality and cardiovascular events during 2 years of
follow-up.17
To date, it is not established whether having more
components of metabolic syndrome further worsens exer-
cise performance in patients with intermittent claudication
or which components of metabolic syndrome are most
associated with exercise performance and peripheral circu-
lation. Therefore, the purposes of this study were to
(1) determine the effect of metabolic syndrome compo-
nentsonintermittentclaudication,physical function,health-
related quality of life, and peripheral circulation in patients
with peripheral arterial disease (PAD), and (2) identify the
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of each outcome measure.
METHODS
Patient screening. A total of 423 PAD patients with
stable symptoms of intermittent claudication andmetabolic
syndrome participated in this study in the Geriatrics, Re-
search, Education, and Clinical Center at the Maryland
Veterans Affairs Health Care System (MVAHCS) at Balti-
more as part of a previous investigation.16 Patients were
recruited from the vascular clinic at the site of the Baltimore
MVAHCS between 1994 and 2002. Patients were in-
cluded in this study if they had Fontaine stage II PAD18
defined by the following inclusion criteria: (1) a history of
intermittent claudication, (2) ambulation during a graded
treadmill test limited by intermittent claudication,7 (3) an
ankle-brachial index (ABI) at rest of 0.90,6 and (4)
presence of metabolic syndrome.13
Patients were excluded from this study for the following
conditions: (1) absence of PAD, (2) inability to obtain an ABI
measure due to noncompressible vessels, (3) asymptomatic
PAD (Fontaine stage I), (4) rest pain PAD (Fontaine stage
III), (5) use of medications indicated for the treatment of
intermittent claudication (cilostazol and pentoxifylline)3
months of the investigation, (6) exercise tolerance limited
by factors other than claudication (eg, severe coronary
artery disease, dyspnea, poorly controlled blood pressure),
(7) active cancer, renal disease, or liver disease, and (8)
absence of metabolic syndrome.
A total of 133 patients were deemed eligible for this
investigation, and 290 patients were ineligible. Of the
ineligible patients, 89 either did not have PAD or were not
limited by intermittent claudication, and the remaining
201 were limited by intermittent claudication but did not
have metabolic syndrome and were described in a previous
report as the control group.16 All patients lived indepen-
dently at home. The Institutional Review Boards at the
University of Maryland and the MVAHCS at Baltimore
approved the procedures used in this study. Written in-
formed consent was obtained from each patient before the
investigation.
Metabolic syndrome classification. According to the
National Cholesterol Education Program (NCEP) Adult
Treatment Panel (ATP) III,13 metabolic syndrome is de-
fined as three or more of the following components:
1. abdominal obesity (waist circumference 102 cm in
men and  88 cm in women);
2. elevated triglycerides (150 mg/dL),
3. reduced high-density lipoprotein cholesterol (40
mg/dL in men and 50 mg/dL in women),
4. elevated blood pressure (130/85 mm Hg), and
5. elevated fasting glucose (110 mg/dL) as well as those
with diabetes.
Although several definitions of metabolic syndrome
exist, the NCEP ATP III definition was used in this inves-
tigation because it was specifically established on a popula-
tion from the United States. In the total group of 423patients, 334 screened positive for PAD. Of these, meta-
bolic syndrome screens were positive in 133 patients (40%)
and negative in the remaining 201 (60%).
Medical history. Demographic information, height,
weight, cardiovascular risk factors, comorbid conditions,
claudication history, and a list of current medications were
obtained during a physical examination andmedical history
interview to begin the evaluation.
Claudication distances and peak oxygen uptake.
Patients performed a progressive, graded treadmill protocol
of 2 mph at 0% grade, with 2% increase every 2 minutes,
until maximal claudication pain, as previously described.7
The initial claudication distance (ICD), absolute claudica-
tion distance (ACD), and peak oxygen uptake were mea-
sured. The test-retest intraclass reliability coefficient for
these procedures is R  0.89 for ICD,7 R  0.93 for
ACD,7 and R  0.88 for peak oxygen uptake.19
Walking economy and fractional utilization.
Oxygen uptake was measured during a constant, submaxi-
mal work rate at a treadmill speed of 2 mph and a grade of
0% until maximal claudication pain, or for a maximum of 20
minutes.20 Walking economy was measured as the oxygen
uptake obtained during the final minute of the test. To
quantify the intensity of the walking economy test as a
percentage of peak capacity, fractional utilization was cal-
culated as the walking economy oxygen uptake/peak oxy-
gen uptake.
ABI and ischemic window. As previously described,
the ABI was obtained from the more severely diseased
lower extremity by the Doppler ultrasound technique be-
fore and at 1, 3, 5, and 7minutes after each treadmill test.21
The reduction in ankle systolic blood pressure after tread-
mill exercise from the resting baseline value was quantified
by calculating the area over the curve (AOC) up to the
resting value, referred to as the ischemic window.22
Six-minute walk test. Patients performed an over
ground, 6-minute walk test supervised by trained exercise
technicians as previously described.23 The pain-free and
total distance walked during the test were recorded. The
test-retest intraclass reliability coefficient is R  0.75 for
distance to onset of claudication pain and R  0.94 for
total 6-minute walking distance.23
Walking Impairment Questionnaire. Self-reported
ambulatory ability was assessed using the Walking Impair-
ment Questionnaire (WIQ), which has been validated for
PAD patients. The WIQ assesses the ability to walk at
various speeds and distances and to climb stairs.24
Short Physical Performance Battery. The Short
Physical Performance Battery score was calculated from the
performance of a 4-m walk test, a chair stand test, and a
standing balance test, as previously described.25,26 For each
of the three tests, patients were scored on a 0 to 4 ordinal
scale, with a score of 0 representing inability to perform the
test, and scores between 1 and 4 representing quartiles of
performance based on normative data from 5000 com-
munity-dwelling people published from the Established
Populations for the Epidemiologic Studies of the Elderly.25The Short Physical Performance Battery score ranges from
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predictive of mobility loss, nursing home placement, and
death among community-dwelling elderly individuals.25,26
The test-retest intraclass reliability coefficient is R  0.93
for the Short Physical Performance Battery score.27
Self-perceived health. The Health Utilities Index
ranging between 0 (the worst imaginable health) and 100
(the best imaginable health) was used to assess self-reported
health as previously described.28 Patients were asked to
select a numeric value on the scale that best corresponded
to their current overall health state.
Daily physical activity. Physical activity level was
monitored for 2 consecutive weekdays by a Caltrac accel-
erometer (Muscle Dynamics, Torrance, Calif) attached to
the belt of each subject, as previously described.9,29 In
addition, a physical activity scale (PAS) was used to assess
the self-reported physical activity level during the preceding
month, as previously described.9,29 The accelerometer
measure of physical activity (test-retest intraclass reliability
coefficient, R  0.84)29 provides a valid estimate of daily
physical activity assessed by the gold standard technique of
doubly labeled water.30
Quality of life. Health-related quality of life was as-
sessed with the Medical Outcomes Study Short-Form 36
(MOS SF-36) General Health Survey.31 TheMOS SF-36 is
a reliable and valid generic instrument that includes multi-
item scales measuring the following eight health domains:
physical function, role limitations due to physical problems,
general health, bodily pain, social function, role limitations
due to emotional problems, mental health, and vitality. For
each subscale, item scores were recorded, summed, and
standardized into a scale from 0 to 100, with better health
states resulting in higher scores.
Calf blood flow. Calf blood flow was obtained at rest
and after 3 minutes of arterial occlusion (ie, reactive hyper-
emia) in the more severely diseased leg using venous occlu-
sion mercury strain-gauge plethysmography, as previously
described.31 The test-retest intraclass reliability coefficient
is R  0.86 for calf blood flow.31
Transcutaneous oxygen tension. Transcutaneous
oxygen tension (TcPO2) was measured at rest and after 3
minutes of arterial occlusion on the medial portion of the
calf musculature of the more affected leg with a Clark-type
polarographic electrode and a TcPO2 Monitor (Model
818, NovametrixMedical Systems IncWallingford, Conn).
The change in calf TcPO2 after arterial occlusion is a
measure of the ischemic response to this test. The test-
retest intraclass reliability coefficient is R  0.87 for calf
TcPO2.
19
Statistical analyses. One-factor analysis of variance
(ANOVA) and Kruskal-Wallis H tests were used for para-
metric and nonparametric measures, respectively, to assess
whether differences in clinical characteristics existed among
the three groups of PAD patients with either three, four, or
five components of metabolic syndrome. All of the
ANOVA tests met the assumption of having normally
distributed data. Analysis of covariance was then used to
assess group differences in claudication distances, physicalfunction measures, health-related quality of life, and pe-
ripheral vascular measures after adjusting for age, ABI,
body mass index (BMI), current smoking, duration of
intermittent claudication, obesity, race, sex, and weight.
To control for multiple testing, significant main effects
were followed by a Tukey test with  0.05 to examine the
three possible comparisons among the group means. In
addition, stepwise multiple regressions were performed to
identify the metabolic syndrome components that were
predictive of claudication distances, physical function mea-
sures, health-related quality of life, and peripheral vascular
measures after adjusting for age, ABI, current smoking,
duration of intermittent claudication, obesity, race, sex,
and weight. Statistical significance was set at P  .05.
Measurements are presented as means  standard devia-
tions. All analyses were performed using the SPSS software
(SPSS Inc, Chicago, Ill).
RESULTS
Differences between metabolic syndrome groups.
By definition, the prevalence of each component of meta-
bolic syndrome (elevated fasting glucose, elevated blood
pressure, elevated triglycerides, reduced high-density li-
poprotein, and abdominal obesity) was 100% in the group
having all five criteria of metabolic syndrome (Table I).
Furthermore, the prevalence of each metabolic syndrome
component was different among the groups (P  .001).
There was a progressive increase in weight (P .001), BMI
(P  .001), and prevalence of obesity (P  .001) as the
number of metabolic syndrome components increased.
The three groups were similar for age, sex, race, ABI,
history of having intermittent claudication, and prevalence
of current smoking (P  .05).
A progressive decline occurred in ICD (P  .022) and
ACD (P  .039) as the number of metabolic syndrome
components increased (Table II). Group differences also
were found for peak oxygen uptake (P  .041), walking
economy (P  .045), fractional utilization (P  .026),
ischemic window after the graded treadmill test (P .035),
and ischemic window after the walking economy test (P 
.026). For each of these measures, the trend was that
patients with three metabolic syndrome components had
the most favorable values, whereas those with five meta-
bolic syndrome components had the least favorable values.
Differences among groups were found for 6-minute
walk pain-free (P  .024) and total (P  .044) distances,
WIQ stair climbing score (P  .021), self-perceived health
(P  .001), physical activity scale (P  .015), and moni-
tored daily physical activity (P  .042; Table III). The
trend was that each measure worsened with an increase in
metabolic syndrome components.
Health-related quality of life was lower with an increase
in metabolic syndrome components (Table IV) for the
domains of physical function (P  .039), role limitations
due to physical problems (P  .016), bodily pain (P 
.041), general health (P  .042), and vitality (P  .031).
As reported in Table V, after vascular occlusion, differ-
ences among groups were found for the percentage in-
.05) u
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and the percentage increase in calf TcPO2 from rest to
hyperemia (P  .043). In both cases, the values in the
patients with five metabolic syndrome components were
lower than those with three components.
Metabolic syndrome components predictive of out-
come measures. For measures obtained during standard-
ized treadmill tests, abdominal obesity was the only meta-
bolic syndrome component that was a predictor for ICD
(P  .019), ACD (P  .015), peak oxygen uptake (P 
.030), walking economy (P .009), and fractional utiliza-
tion (P  .001; Table II). Elevated fasting glucose was the
only metabolic syndrome component that was a predictor
for ischemic window after the graded treadmill test (P 
Table I. Clinical characteristics of peripheral arterial disea
syndrome
Variables a
Meta
3 (n  48)
Age, y 69 (5)
Weight, kg 82.3 (16.2)
Body mass index 28.1 (4.6)
Ankle-brachial index 0.65 (0.25)
IC duration, years 4.8 (4.3)
Sex, % men 83
Race, % Caucasian 62
Current smoking, % 34
Elevated fasting glucose, % 57
Elevated blood pressure, % 59
Elevated triglycerides, % 74
Reduced HDL cholesterol, % 68
Abdominal obesity, % 38
Obesity, %e 26
HDL, High-density lipoprotein; IC, intermittent claudication.
aValues are means (SD) and percentages.
bGroup difference.
cDifferent than group with three metabolic syndrome components (P  .0
dDifferent than the group with four metabolic syndrome components (P 
eObesity was defined as having a body mass index  30 kg/m2.
Table II. Treadmill measurements of peripheral arterial d
metabolic syndrome
Variables a
Metabolic syndrom
3 (n  48) 4 (n
ICD, m 201 (165) 125 (
ACD, m 411 (221) 322 (
Peak oxygen uptake, mL/kg/min 15.1 (3.2) 13.1 (
Walking economy, mL/kg/min 11.8 (1.9) 12.0 (
Fractional utilization, % 78 (17) 92 (
Ischemic window (min  mm Hg)
After graded treadmill test 153 (137) 194 (
After walking economy test 77 (79) 125 (
ACD, Absolute claudication distance; AO, abdominal obesity; EFG, elevate
aValues are adjusted for age, ankle-brachial index, body mass index, current
are presented as means (SD).
bDifferent than the group with three metabolic syndrome components (P 
cDifferent than the group with four metabolic syndrome components (P .029) and after the walking economy test (P  .017).For measures of physical function and physical activity
(Table III), abdominal obesity was themetabolic syndrome
component that was a predictor for 6-minute walk pain-
free distance (P .047), 6-minute walk total distance (P
.006), physical activity scale (P  .029), and monitored
daily physical activity (P  .046), whereas elevated fasting
glucose was the predictor for WIQ distance (P  .014),
speed (P  .011) and stair climbing (P  .039), as well as
self-perceived health (P  .001).
Elevated fasting glucose was the predictor for the
health-related quality of life domains (Table IV) of physical
function (P  .045), role limitations due to physical prob-
lems (P  .015), bodily pain (P  .037), role limitations
due to emotional problems (P  .025), and vitality (P 
tients with three, four, or five components of metabolic
syndrome component groups
Pb4 (n  45) 5 (n  40)
68 (7) 66 (7) 0.137
87.5 (13.8)c 95.9 (14.7)c,d  .001
30.5 (4.2)c 32.7 (4.2)c,d  .001
0.70 (0.25) 0.69 (0.22) 0.498
5.7 (5.6) 4.9 (3.9) 0.376
78 80 0.495
63 58 0.512
35 30 0.857
66 100c,d  .001
88c 100c,d  .001
87 100c,d  .001
90c 100c  .001
90c 100c  .001
54c 73c,b  .001
g Tukey test.
using Tukey test.
patients with three, four, or five components of
ponent groups P values
5 (n  40) Group difference Predictors
81 (58)b,c .022 AO (.019)
b 251 (148)b,c .039 AO (.015)
12.9 (2.7)b .041 AO (.030)
12.3 (2.8)b .045 AO (.009)
95 (15)b .026 AO (.001)
217 (160)b .035 EFG (.029)
b 128 (101)b .026 EFG (.017)
ing glucose; ICD, initial claudication distance.
g, duration of intermittent claudication, obesity, race, sex, and weight, and
using Tukey test.
sing Tukey test.se pa
bolic
5) usin
.05)isease
e com
 45)
76)b
151)
2.6)b
2.7)
18)b
143)
104)
d fast
smokin
.05).027). Elevated fasting glucose (P  .001) and abdominal
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Volume 47, Number 6 Gardner and Montgomery 1255Table III. Physical function, self-reported health, and physical activity level of peripheral arterial disease patients with
three, four, or five components of metabolic syndrome
Variables a
Metabolic syndrome components P values
3 (n  48) 4 (n  45) 5 (n  40) Group difference Predictors
6-minute walk
Pain-free distance, m 205 (124) 167 (113)b 128 (97)b .024 AO (.047)
Distance, m 371 (82) 344 (90)b 295 (92)b .044 AO (.006)
WIQ score
Distance, % 33 (29) 29 (31) 27 (30)b .069 EFG (.014)
Speed, % 32 (24) 26 (27) 24 (22)b .057 EFG (.011)
Stair climbing, % 36 (31) 33 (30)b 31 (27)b .021 EFG (.039)
SPPB (points) 10.1 (1.2) 1.0 (1.2) 9.7 (1.4) .178 None
Self-perceived health, % 73 (18) 64 (20)b 64 (17)b .001 EFG (.001)
Physical activity scale, (points) 1.4 (1.0) 1.1 (1.0)b 1.0 (1.0)b .015 AO (.029)
Daily physical activity, kcal/d 343 (184) 317 (160) 295 (140)b .042 AO (.046)
AO, Abdominal obesity; EFG, elevated fasting glucose; SPPB, Short Physical Performance Battery; WIQ, walking impairment questionnaire.
aValues are adjusted for age, ankle-brachial index, body mass index, current smoking, duration of intermittent claudication, obesity, race, sex and weight, and
are presented as means (SD).
bDifferent than group with three metabolic syndrome components (P  .05) using Tukey test.Table IV. Health-related quality-of-life measurements of peripheral arterial disease patients with three, four, or five
components of metabolic syndrome
Domain scores a
Metabolic syndrome components P value
3 (n  48) 4 (n  45) 5 (n  40) Group difference Predictors
Physical function, % 48 (26) 46 (20) 42 (20)b .039 EFG (.045)
Role limitations–physical, % 56 (41) 37 (41)b 24 (39)b .016 EFG (.015)
Bodily pain, % 58 (23) 43 (19)b 41 (16)b .041 EFG (.037)
General health, % 53 (20) 46 (23)b 45 (21)b .042 EFG (.001); AO (.038)
Social function, % 72 (22) 72 (28) 71 (21) .722 None
Role limitations–emotional, % 66 (39) 55 (44) 36 (38)b .071 EFG (.025)
Mental health, % 80 (16) 81 (16) 72 (18) .352 None
Vitality score, % 63 (15) 52 (16) 41 (25)b .031 EFG (.027)
AO, Abdominal obesity; EFG, elevated fasting glucose.
aDomain scores are adjusted for age, ankle/brachial index, body mass index, current smoking, duration of intermittent claudication, obesity, race, sex and
weight, and are presented as means (SD).
bDifferent than group with three metabolic syndrome components (P  .05) using Tukey test.Table V. Peripheral hemodynamic measurements of peripheral arterial disease patients with three, four, or five
components of metabolic syndrome
Variables a
Metabolic syndrome components P value
3 (n  48) 4 (n  45) 5 (n  40) Group difference Predictors
Calf blood flow
Rest, %/min 3.73 (1.61) 3.68 (1.52) 3.57 (1.30) .068 None
Hyperemia, %/min 8.94 (3.71) 8.82 (4.27) 8.24 (4.00) .589 None
Change from rest to hyperemia, % 180 (153) 137 (111) 129 (108)b .043 EFG (.021)
Calf TcPO2
Rest, mm Hg 38 (19) 38 (17) 33 (15) .082 None
Hyperemia, mm Hg 24 (20) 20 (16) 17 (16) .087 None
Change from rest to hyperemia, % –37 (38) –47 (42) –48 (52)b .043 EFG (.019) AO (.047)
AO, Abdominal obesity; EFG, elevated fasting glucose; TcPO2, transcutaneous oxygen pressure.
aValues are adjusted for age, ankle-brachial index, body mass index, current smoking, duration of intermittent claudication, obesity, race, sex and weight,
and are presented as means (SD).
bDifferent than group with 3 metabolic syndrome components group (P  .05) using Tukey test.
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general health.
For peripheral hemodynamic measures (Table V), ele-
vated fasting glucose was the predictor for the percentage
increase in calf blood flow (P  .021), whereas elevated
fasting glucose (P  .019) and abdominal obesity (P 
.047) were both predictors for the percentage increase in
calf blood flow.
DISCUSSION
The major findings of this investigation were that (1)
patients limited by intermittent claudication who had more
components of metabolic syndrome had shorter claudica-
tion distances, lower cardiopulmonary function, impaired
ambulatory function, lower physical activity, lower health-
related quality of life, and diminished peripheral circulation
than patients with fewer components of metabolic syn-
drome, and (2) abdominal obesity was the predictor of
exercise performance and physical activity, whereas elevated
fasting glucose was the predictor of peripheral circulation,
self-perceived walking ability and health, and health-related
quality of life.
The ambulatory dysfunction of PAD patients limited
by intermittent claudication is exacerbated by having a
greater burden of metabolic syndrome. Patients with all five
components of metabolic syndrome experienced ICD and
ACD sooner than those with only three components and
had greater impairments in peak oxygen uptake, walking
economy, and fractional utilization as well. Thus, a greater
burden of metabolic syndrome worsens claudication and
cardiopulmonary fitness in patients limited by intermittent
claudication, independent of BMI, weight, and obesity.
The adjustment for these factors indicates that the
impaired exercise performance of patients with five compo-
nents of metabolic syndrome was not merely related to the
added burden of walking due to their greater body
mass.32,33 Rather, the clustering of risk factors that com-
prise the metabolic syndrome, particularly abdominal obe-
sity, negatively affects exercise performance of patients with
PAD. These data support previous findings that metabolic
syndrome impairs ICD and ACD in patients with intermit-
tent claudication16,17 and lowers cardiopulmonary fitness
in adult men and women34 and in patients with intermit-
tent claudication.16 As a consequence, PAD patients with
metabolic syndrome may have difficulty completing activi-
ties of daily living that require relatively high intensities,
and this trendmay becomemore prominent with a progres-
sive increase in metabolic syndrome burden.
In addition to their poorer exercise performance during
standardized treadmill tests, PAD patients with all five
components of metabolic syndrome had a more rapid rate
of claudication pain during the less intensive 6-minute walk
test than in those with only three components. Abdominal
obesity was the metabolic syndrome component that was a
predictor of exercise performance during the 6-minute
walk test, which is consistent with the findings for the
treadmill performance measures. Furthermore, those with
the greatest burden of metabolic syndrome also had lowerself-perceived ability to climb stairs. These greater impair-
ments in ambulation in patients with all five components of
metabolic syndrome resulted in lower self-perceived health
and lower health-related quality of life scores on all domains
except for role limitations due to emotional problems,
mental health, and social functioning.
Metabolic syndrome diminishes the peripheral circula-
tion of PAD patients limited by intermittent claudica-
tion,16,17 and this trend increases as the number of compo-
nents of metabolic syndrome increase. Patients with all five
components of metabolic syndrome had greater calf isch-
emia and lower calf blood flow in response to vascular
occlusion than those with only three components of
metabolic syndrome as well as greater ischemic window
values after standardized treadmill exercise. Elevated
fasting glucose was the metabolic syndrome component
that was a predictor of these peripheral circulation mea-
sures, suggesting that insulin resistance plays a role in the
ischemic response of PAD patients limited by intermit-
tent claudication.
The clinical relevance of this study is that PAD patients
limited by intermittent claudication who have all five com-
ponents of metabolic syndrome have the greatest ambula-
tory dysfunction. As a consequence, the additive burden of
having all of the metabolic syndrome components places
patients limited by intermittent claudication at greatest risk
for living a functionally dependent lifestyle and for subse-
quent mobility loss26 than patients who have fewer com-
ponents of metabolic syndrome.
Although all components of metabolic syndrome
should be treated, the clinical management of abdominal
obesity and elevated fasting glucose may be particularly
important in modifying physical function and peripheral
circulation in patients with intermittent claudication. In
speculation, some of the beneficial aspects of exercise reha-
bilitation in these patients35 may result from adaptations in
metabolic syndrome. Future intervention trials are needed
to extend the preliminary findings of the current study.
This study has several limitations. The cross-sectional
design comparing patients with three, four, and five com-
ponents of metabolic syndrome does not allow causality to
be established, because it is possible that those with five
components had the most impaired intermittent claudica-
tion, physical function, health-related quality of life, and
peripheral circulation before they had all components of
metabolic syndrome.
Another limitation is that the location of the arterial
lesions was not determined, thus preventing group com-
parison on the distribution of lesion location. In addition,
the results are generalizable to PAD patients with a
history of leg pain and who are limited by leg pain during
a standardized treadmill test, regardless of whether the
leg pain is typical or atypical of intermittent claudication.
Thus, the present findings cannot be generalized to
patients with asymptomatic PAD or to those who are
limited in their exercise performance by other significant
comorbid conditions.
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 6 Gardner and Montgomery 1257Most of the participants were veterans, and conse-
quently, men comprised approximately 80% of the sample,
which is another limitation. However, African Americans
were well represented in this sample, as were patients with
typical risk factors for PAD, including smoking, diabetes,
hypertension, dyslipidemia, and obesity. Thus, in patients
limited by leg pain, the findings of the present study are
generalizable to the large proportion with numerous co-
morbid conditions.
CONCLUSION
Patients with PADwho havemoremetabolic syndrome
components have worsened intermittent claudication,
physical function, health-related quality of life, and periph-
eral circulation. Furthermore, abdominal obesity and ele-
vated fasting glucose are the metabolic syndrome compo-
nents that are most predictive of these outcome measures.
Aggressively treating these metabolic syndrome compo-
nents may be particularly important in managing symptom-
atology and long-term prognosis of PAD patients.
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